EUCTR2011-006239-44-NL
Active, not recruiting
Not Applicable
An international collaborative study to discontinue Imatinib/Glivec® in pediatric CML patients with sustained complete molecular response(STOPIMAPED) - STOPIMAPED
Dutch Childhood Oncology Group0 sites60 target enrollmentStarted: October 2, 2012Last updated:
ConditionsChronic Myeloid Leukemia pediatric patients treated with Imatinib having achieved and maintained complete molecular remission for at least 2 years.Therapeutic area: Diseases [C] - Cancer [C04]
DrugsGlivec Filmtabletten
Overview
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- Dutch Childhood Oncology Group
- Enrollment
- 60
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •Pediatric CML patients treated with Imatinib having achieved and maintained complete molecular remission for at least 2 years.
- •Informed consent needs to be signed.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 12
- •F.1\.2 Adults (18\-64 years) no
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) no
- •F.1\.3\.1 Number of subjects for this age range
Exclusion Criteria
- •Non\-CML patients, or CML patients with complete cytogenetic reponse but with a moderate molecular response.
Investigators
Similar Trials
Completed
Phase 4
An international collaborative study to discontinue Imatinib/Glivec® in pediatric CML patients with sustained complete molecular responsechronic myeloid leukemia10024324NL-OMON39021Stichting Kinderoncologie Nederland6
Not yet recruiting
Not Applicable
An international collaborative study to discontinue Imatinib/Glivec® in pediatric CML patients with sustained complete molecular response (STOPIMAPED).CMLchildrenstop Imatinib/Glivec®complete molecular responseNL-OMON23324SKION/DCOG (Stichting Kinderoncologie Nederland)Leyweg 2992545CJ Den Haag60
Completed
Phase 1
Pilot study "International collaborative investigation of underlying technology to develop information exchange platform with hairdresser and barber for successful aging in Thailand and Japan"Shop owner and customers in hairdresser/barberJPRN-UMIN000023733Akita University12
Recruiting
Phase 1
International study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the efficacy of Vinblastinestandard risk ALK-positive anaplastic large cell lymphoma (ALCL)Therapeutic area: Diseases [C] - Neoplasms [C04]CTIS2022-501454-11-00GPOH gGmbH132
Recruiting
Phase 3
International cooperative prospective study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the efficacy of VinblastineDRKS00023541Gesellschaft für pädiatrische Hämatologie und Onkologie (GPOH) gGmbH106